Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06274385 · ClinicalTrials.gov registry record · NA
The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.
A NA study of Nutraceuticals, sponsored by Drexel University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06274385 is a NA study of Nutraceuticals that is actively recruiting participants, run by Drexel University. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06274385, a NA study of Nutraceuticals, is actively recruiting participants, sponsored by Drexel University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Betalains have well-known antioxidant and anti-inflammatory properties. Recent investigations examining the effects of a betalain-rich concentrate (BRC) on exercise and recovery performance show promise of BRC as an ergogenic aid. To date, no study has examined the effects of a single dose of a BRC on supramaximal performance and recovery. Therefore, the purpose of this study is to examine the effects of an acute dose of BRC on repeated-sprint cycling performance and recovery.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Betalain-rich concentrate (AltRed)
Study Locations (1)
Pennsylvania
- Drexel University - Health Sciences Building - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2025-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06274385
The ClinicalTrials.gov registry entry for NCT06274385 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Drexel University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nutraceuticals appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06274385 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06274385 about?
NCT06274385 is a clinical study titled "The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.". Betalains have well-known antioxidant and anti-inflammatory properties. Recent investigations examining the effects of a betalain-rich concentrate (BRC) on exercise and recovery performance show promise of BRC as an ergogenic aid. To date, no study has examined the effects of a single dose of a BRC ...
What is the current status of trial NCT06274385?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2024-03-06. Estimated completion is 2025-08.
What conditions does trial NCT06274385 study?
This clinical trial studies the following conditions: Nutraceuticals.
What interventions are being tested in trial NCT06274385?
The interventions under investigation include: Placebo (OTHER), Betalain-rich concentrate (AltRed) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06274385?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06274385 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.